33,455 XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Raffi Asadorian | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.67 per share. | 14 Feb 2025 | 3,245 | 32,214 (0%) | 0% | 0.7 | 2,174 | Common Stock |
| Badri Dasu | Chief Engineering Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.67 per share. | 14 Feb 2025 | 2,644 | 27,011 (0%) | 0% | 0.7 | 1,771 | Common Stock |
| Vincent J. Angotti | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.67 per share. | 14 Feb 2025 | 10,575 | 190,459 (0%) | 0% | 0.7 | 7,085 | Common Stock |
| Raffi Asadorian | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.62 per share. | 10 Feb 2025 | 1,060 | 35,459 (0%) | 0% | 0.6 | 657 | Common Stock |
| Raffi Asadorian | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.63 per share. | 10 Feb 2025 | 1,059 | 36,519 (0%) | 0% | 0.6 | 667 | Common Stock |
| Badri Dasu | Chief Engineering Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.62 per share. | 10 Feb 2025 | 880 | 29,655 (0%) | 0% | 0.6 | 546 | Common stock |
| Badri Dasu | Chief Engineering Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.63 per share. | 10 Feb 2025 | 879 | 30,535 (0%) | 0% | 0.6 | 554 | Common Stock |
| Vincent J. Angotti | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.62 per share. | 10 Feb 2025 | 3,517 | 201,034 (0%) | 0% | 0.6 | 2,181 | Common Stock |
| Vincent J. Angotti | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.63 per share. | 10 Feb 2025 | 3,515 | 204,551 (0%) | 0% | 0.6 | 2,214 | Common Stock |
| Vincent J. Angotti | Director, CHIEF EXECUTIVE OFFICER | Purchase of securities on an exchange or from another person at price $ 0.64 per share. | 05 Dec 2024 | 5,000 | 208,066 (0%) | 0% | 0.6 | 3,200 | Common Stock |
| Raffi Asadorian | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.77 per share. | 02 Dec 2024 | 155 | 37,578 (0%) | 0% | 0.8 | 119 | Common Stock |
| Vincent J. Angotti | Director, CHIEF EXECUTIVE OFFICER | Purchase of securities on an exchange or from another person at price $ 0.73 per share. | 27 Nov 2024 | 5,000 | 203,066 (0%) | 0% | 0.7 | 3,650 | Common Stock |
| Vincent J. Angotti | Director, CHIEF EXECUTIVE OFFICER | Purchase of securities on an exchange or from another person at price $ 1.05 per share. | 30 Aug 2024 | 7,260 | 198,066 (0%) | 0% | 1.0 | 7,598 | Common Stock |
| Stephen J. Hoffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 2,174 | 4,592 (0%) | 0% | 0 | Common Stock | |
| Jill M. Broadfoot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 13,044 | 13,044 | - | - | Stock Option (Right to Buy) | |
| Stephen J. Hoffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 13,044 | 13,044 | - | - | Stock Option (Right to Buy) | |
| Adrian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 13,044 | 13,044 | - | - | Stock Option (Right to Buy) | |
| Mark A. Wan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 13,044 | 13,044 | - | - | Stock Option (Right to Buy) | |
| Mark A. Wan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 2,174 | 4,592 (0%) | 0% | 0 | Common Stock | |
| Adrian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 2,174 | 13,342 (0%) | 0% | 0 | Common Stock | |
| Jill M. Broadfoot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 2,174 | 4,280 (0%) | 0% | 0 | Common Stock | |
| Marina Bozilenko | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 2,174 | 4,780 (0%) | 0% | 0 | Common Stock | |
| Marina Bozilenko | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 13,044 | 13,044 | - | - | Stock Option (Right to Buy) | |
| Abhinav Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 13,044 | 13,044 | - | - | Stock Option (Right to Buy) | |
| Abhinav Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 2,174 | 3,045 (0%) | 0% | 0 | Common Stock | |
| Shakil Aslam | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 0.98 per share. | 13 Jun 2024 | 695 | 32,695 (0%) | 0% | 1.0 | 681 | Common Stock |
| Aslam Shakil | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 1.07 per share. | 13 Jun 2024 | 5,000 | 37,695 (0%) | 0% | 1.1 | 5,357 | Common Stock |
| Vincent J. Angotti | Director, CHIEF EXECUTIVE OFFICER | Purchase of securities on an exchange or from another person at price $ 1.08 per share. | 12 Jun 2024 | 1,304 | 180,806 (0%) | 0% | 1.1 | 1,404 | Common Stock |
| Vincent J. Angotti | Director, CHIEF EXECUTIVE OFFICER | Purchase of securities on an exchange or from another person at price $ 0.97 per share. | 12 Jun 2024 | 4,126 | 174,932 (0%) | 0% | 1.0 | 4,013 | Common Stock |
| Vincent J. Angotti | Director, CHIEF EXECUTIVE OFFICER | Purchase of securities on an exchange or from another person at price $ 0.97 per share. | 12 Jun 2024 | 4,570 | 179,502 (0%) | 0% | 1.0 | 4,438 | Common Stock |
| Vincent J. Angotti | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 1.12 per share. | 11 Mar 2024 | 1,000 | 162,806 (0%) | 0% | 1.1 | 1,115 | Common Stock |
| Vincent J. Angotti | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 1.12 per share. | 11 Mar 2024 | 8,000 | 170,806 (0%) | 0% | 1.1 | 8,995 | Common Stock |
| Vincent J. Angotti | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.30 per share. | 03 Mar 2024 | 1,623 | 161,806 (0%) | 0% | 1.3 | 2,110 | Common Stock |
| Pamela P. Palmer | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.30 per share. | 03 Mar 2024 | 450 | 59,149 (0%) | 0% | 1.3 | 585 | Common Stock |
| Raffi Asadorian | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.30 per share. | 03 Mar 2024 | 558 | 37,733 (0%) | 0% | 1.3 | 725 | Common Stock |
| Badri Dasu | Chief Engineering Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.30 per share. | 03 Mar 2024 | 406 | 31,414 (0%) | 0% | 1.3 | 528 | Common Stock |
| Asadorian Raffi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 18,000 | 38,291 (0%) | 0% | 0 | Common Stock | |
| Asadorian Raffi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 108,000 | 108,000 | - | - | Stock Option (Right to Buy) | |
| Pamela Palmer P. | Director, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 18,000 | 53,344 (0%) | 0% | 0 | Common Stock | |
| Palmer Pamela P. | Director, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 108,000 | 108,000 | - | - | Stock Option (Right to Buy) | |
| Badri Dasu | Chief Engineering Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 88,000 | 88,000 | - | - | Stock Option (Right to Buy) | |
| Angotti J. Vincent | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 352,000 | 352,000 | - | - | Stock Option (Right to Buy) | |
| J. Angotti Vincent | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 58,667 | 153,429 (0%) | 0% | 0 | Common Stock | |
| Badri Dasu | Chief Engineering Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 14,667 | 31,820 (0%) | 0% | 0 | Common Stock | |
| Badri Dasu | Chief Engineering Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.10 per share. | 10 Feb 2024 | 809 | 17,962 (0%) | 0% | 1.1 | 890 | Common Stock |
| Vincent Angotti J. | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.10 per share. | 10 Feb 2024 | 3,723 | 94,762 (0%) | 0% | 1.1 | 4,095 | Common Stock |
| Angotti J. Vincent | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.10 per share. | 10 Feb 2024 | 3,320 | 98,485 (0%) | 0% | 1.1 | 3,652 | Common Stock |
| Badri Dasu | Chief Engineering Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.10 per share. | 10 Feb 2024 | 809 | 17,153 (0%) | 0% | 1.1 | 890 | Common Stock |
| Pamela Palmer P. | Director, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.10 per share. | 10 Feb 2024 | 801 | 36,145 (0%) | 0% | 1.1 | 881 | Common Stock |
| Raffi Asadorian | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.10 per share. | 10 Feb 2024 | 895 | 21,186 (0%) | 0% | 1.1 | 985 | Common Stock |
| Raffi Asadorian | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.10 per share. | 10 Feb 2024 | 895 | 20,291 (0%) | 0% | 1.1 | 985 | Common Stock |
| Pamela Palmer P. | Director, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.10 per share. | 10 Feb 2024 | 801 | 35,344 (0%) | 0% | 1.1 | 881 | Common Stock |